Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer

William J. Gradishar, Dimitry Krasnojon, Sergey Cheporov, Anatoly N. Makhson, Georgiy M. Manikhas, Alicia Clawson, Paul Bhar

Research output: Contribution to journalArticlepeer-review

311 Scopus citations

Fingerprint

Dive into the research topics of 'Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer'. Together they form a unique fingerprint.

INIS

Pharmacology, Toxicology and Pharmaceutical Science